Wikipedia -WSS

Wikipedia

author：focus 2025-08-12 09:13:17 - browse：9315

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Type 2 diabetes prevention programs work at large scale: study

WSS

Healthy food access boosts outcomes in two studies

NIH chief: government has fallen behind pharma on clinical trials

Change Healthcare cyberattack shows risk of industry consolidation

Virtual repurposing can help discover new uses for existing drugs

What is STAT's opinion section for?

Ventyx halts psoriasis drug development after lackluster trial results

Wikipedia

Wikipedia

focus

Wildfire smoke exposes gaps in outdoor worker protections

Study suggests Covid rebound is far more common with Paxlovid than without

Jerome Adams on the need for new antivirals for Covid

NEJM study measures Covid brain fog, impact on IQ

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Medicare details structure of new drug price negotiation program

Medicare isn't yet testing food as medicine

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

leisure time

Medicare’s new pay boost for primary care is angering specialists

Laying a path for careers in science

What is STAT's opinion section for?

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Readout Newsletter: Zepbound, Valneva's vaccine, and more

hotspot

hotspot

hotspot

hotspot